Dr Mark Nathan, Consultant Medical Oncologist

Dr Mark Nathan

Consultant Medical Oncologist

Book online
|

Dr Mark Nathan MBBS MRCP PhD

Consultant Medical Oncologist

MBBS MRCP PhD

Dr Mark Nathan

Consultant Medical Oncologist MBBS MRCP PhD

Book online
|
MBBS MRCP PhD
HCA-Healthcare-UK

Areas of expertise

  • Breast Cancer
  • Medical Oncology
HCA-Healthcare-UK

Address

About Dr Mark Nathan

GMC number: 6147674

Year qualified: 2006

Place of primary qualification: University of London

Dr Mark Nathan is a Consultant Medical Oncologist at Guy's and St Thomas' NHS Foundation Trust, having joined the team in 2017. He specialises in treating breast cancer and works at Guy's Hospital, King's Hospital, and Queen Mary's Hospital in Sidcup. Dr Nathan is actively involved in the running of clinical trials at Guy's Hospital, contributing to advancements in cancer treatment.

Originally from London, Dr Nathan graduated from Bart's and The London Medical School in 2006. He completed his basic medical training in North East London before returning to St Bartholomew's Hospital for his higher Oncology training. His dedication to breast cancer research led him to spend three years obtaining his PhD as an AVON clinical research fellow at the Breakthrough Breast Cancer Research Centre. During this time, he also participated in clinics at the Royal Marsden Hospital.

Dr Nathan's areas of expertise include the management of early and metastatic breast cancer. He is proficient in a range of medical tests and treatments aimed at improving patient outcomes. His commitment to patient care and research ensures that he remains at the forefront of oncology advancements.

In his role, Dr Nathan is dedicated to providing comprehensive care to his patients, utilising the latest research and clinical practices. His interests lie in improving treatment protocols and patient quality of life through innovative clinical trials and personalised care plans.

Areas of expertise

  • Biological Therapy
  • Breast Cancer
  • Chemotherapy
  • Immunotherapy
  • Medical Oncology
  • Neoadjuvant